Resources
79 Results (showing 41 - 50)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/16/2020 (updated 3/28/2024)
This cross-sectional study included all counties and county-equivalent divisions in the US in 2016. Data on racial/ethnic population distribution were derived from the American Community Survey, and data on locations of facilities providing methadone and buprenorphine were obtained from Substance Abuse and Mental Health Services Administration databases.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 11/21/2019 (updated 3/28/2024)
This report is designed to help drug court practitioners understand medication assisted treatment (MAT) for opioid addiction and to provide strategies for incorporating MAT into their practice.
Posted 5/11/2020 (updated 3/28/2024)
The United States is in the midst of an epidemic of prescription opioid overdoses. The amount of opioids prescribed and sold in the US quadrupled since 1999, but the overall amount of pain reported by Americans hasn’t changed. This epidemic is devastating American lives, families, and communities.
Posted 5/11/2020 (updated 3/28/2024)
This fact sheet describes changes to Oregon Health Authority (OHA) reimbursement for Medication-Assisted Treatment drugs administered to fee-for-service Oregon Health Plan members, effective January 1, 2019.
Posted 11/19/2019 (updated 3/28/2024)
This document is to assist community leaders, local and regional organizers, non-profit groups, law enforcement, public health, and members of the public in understanding and navigating effective strategies to prevent opioid overdose in their communities.
Posted 8/24/2020 (updated 3/28/2024)
Medications for opioid use disorder, including buprenorphine hydrochloride and methadone hydrochloride, are highly effective at improving outcomes for individuals with the disorder. For pregnant women, use of these medications also improves pregnancy outcomes, including the risk of preterm birth. Despite the known benefits of medications for opioid use disorder, many pregnant and nonpregnant women with the disorder are not receiving them.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.